文献速递血栓与止血

直接口服抗凝药在慢性肾脏病中的应用

The use of direct oral anticoagulants in chronic kidney disease.
PubMed 文献 · Br J Haematol · 2018-09-05

本文综述III期试验和真实世界研究中直接口服抗凝药(DOACs)在中重度肾功能不全患者中的安全性和有效性,澄清相关误解,并强调准确评估肾功能以指导DOAC剂量选择的重要性,指出注册数据显示剂量调整不一致可能导致可避免的血栓栓塞和出血事件。

要点

  • DOACs均有一定程度经肾排泄,肾功能不全时使用需谨慎。
  • 综述III期试验和真实世界研究,澄清中重度肾功能不全中DOACs的安全性和有效性误解。
  • 准确评估肾功能以确定DOAC剂量至关重要,注册数据显示剂量调整不一致。

核心结论

  • 综述旨在为临床医生在肾功能不全患者中做出抗凝决策提供资源,以指导选择最合适的药物。

研究设计与样本

  • 本文为综述,总结了III期试验和真实世界研究文献,并讨论了正确评估肾功能以确定DOAC剂量的重要考虑。

主要发现

  • DOACs均具有不同程度的肾排泄,合并肾功能损害可能使DOACs的使用成为问题。
  • 注册数据表明DOAC剂量调整不一致,可能导致可避免的血栓栓塞和出血事件。

临床怎么用

  • 希望本综述能作为参与肾功能不全患者抗凝决策的临床医生的宝贵资源,以指导选择最合适的药物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increasing use of direct oral anticoagulants (DOACs) has made management of non-valvular atrial fibrillation and venous thromboembolism easier in most patients. But the presence of co-existing renal impairment could render the use of DOACs problematic because all of these drugs have varying degrees of renal excretion. In this paper we address misconceptions about the safety and efficacy of DOACs in moderate-severe renal impairment by presenting a summary of the literature from phase III trials and real-world studies. It also addresses the important consideration of correct estimate of renal function for DOAC dosing. It is hoped that the review will serve as a valuable resource for clinicians involved in anticoagulation decision-making in patients with renal impairment to guide the choice of most suitable agent. Accurate dosing is of particular relevance as registry data suggests it is done inconsistently and may be resulting in avoidable thromboembolic and bleeding events.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. Br J Haematol. 2018. PMID: 30183070. doi:10.1111/bjh.15564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。